Estimation of the Epidemiological and Economic Burden of RSV and Influenza Infection in the Hospital Setting Among Adults 65 Years and Older in France

Speaker(s)

Nuttens C1, Barbet V2, Watier L3, Loubet P4, Casalegno JS5, Vanhems P6, Lilliu H7, Fiévez S8, Fahfouhi Y9, Blanc E10, Begier E11, Lemaitre M12
1Pfizer, Paris, 75, France, 2HORIANA, BORDEAUX, 33, France, 3Inserm, UVSQ, Institut Pasteur, Paris-Saclay University, Montigny-Le-Bretonneux, France, 4CHU Nimes, Nimes, 30, France, 5CHU LYON, LYON, 69, France, 6Hospices Civils de Lyon, Lyon, France, 7Inbeeo, London, LON, UK, 8Pfizer SAS France, Paris, 75, France, 9Pfizer, Paris, France, 10Pfizer SAS France, Paris, France, 11Pfizer Inc., Collegeville, PA, USA, 12HORIANA, Bordeaux, France

Presentation Documents

Influenza and respiratory syncytial virus (RSV) are recognized as major causes of respiratory and cardiac acute disease among older adults. While the epidemiologic and economic burden of influenza is well characterized, the burden of RSV is poorly described and underestimated in this population due to insufficient testing.

OBJECTIVES: The objectives of this study were to estimate the incidence of hospitalized RSV infection and its associated economic burden in adults over 65 years old in France, and to compare with influenza.

METHODS: An ecological approach using cyclic regression models integrating the indicators of RSV and influenza circulation, time trends, and seasonal terms was used to estimate excess hospitalizations from July 2010 to February 2020 (hospital discharge database, PMSI) attributable to RSV and influenza. Patient characteristics and medical costs were collected from RSV-positive patients from 2015 to 2019 and the average costs applied to the estimated incidences.

RESULTS: Over the study period, the average annual hospitalization rates attributable to RSV in adults 65 years and older were 174 hospitalizations per 100,000 inhabitants for respiratory causes representing 20,904 hospitalizations. In comparison, those attributable to influenza were 180/100,000 representing 21,732 hospitalizations.

The average length of stay was 12,1 days for RSV and 10,7 days for influenza. 23% of patients hospitalized for RSV and 17% for influenza had at least one stay in intensive or resuscitation unit. The annual average cost estimated was 104 million euros for RSV and 102 million euros for influenza.

CONCLUSIONS: The initial results demonstrated that RSV is responsible for a hospital burden similar to influenza infection among adults 65 years and older, for both incidence and economic consideration. The present study demonstrates that implementing prevention policies for RSV in addition to influenza in France, may have a major impact.

Code

EPH233

Topic

Economic Evaluation

Disease

Infectious Disease (non-vaccine), Vaccines